Related Experiment Video
Updated: Oct 2, 2026

PRP as a New Approach to Prevent Infection: Preparation and In vitro Antimicrobial Properties of PRP
Published on: April 9, 2013
In-vitro activity of RP 59500, a new semisynthetic injectable pristinamycin against staphylococci
1Institute of Medical Microbiology, Westfälische Wilhelms-Universität Münster, Germany.
Abstract:
We compared the in vitro activity of RP 59500, a new streptogramin, with that of vancomycin and ciprofloxacin against 130 strains of S. aureus and 117 strains of coagulase-negative staphylococci, using the agar dilution method. The antistaphylococcal activity of RP 59500 was similar to that of vancomycin. All staphylococcal strains were inhibited by < or = 2 micrograms/mL, including 61 methicillin-resistant S. aureus, 28 methicillin-resistant S. epidermidis and 23 methicillin-resistant S. haemolyticus strains. In contrast to ciprofloxacin, the in vitro activity of RP 59500 as well as of vancomycin remained almost unchanged, irrespective of the resistance phenotype for methicillin.
Insights
RP 59500, a novel streptogramin antibiotic, demonstrates potent in vitro antistaphylococcal activity comparable to vancomycin. It effectively inhibits both methicillin-susceptible and resistant strains of Staphylococcus aureus and coagulase-negative staphylococci.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Staphylococcal infections pose a significant threat, with increasing resistance to existing antibiotics.
- Methicillin-resistant Staphylococcus aureus (MRSA) presents a particular challenge in clinical settings.
- Novel antimicrobial agents are crucial for combating resistant bacterial strains.
Purpose of the Study:
- To evaluate the in vitro efficacy of RP 59500, a new streptogramin, against staphylococci.
- To compare the activity of RP 59500 with vancomycin and ciprofloxacin.
- To assess the impact of methicillin resistance on the activity of these agents.
Main Methods:
- Agar dilution method was employed for antimicrobial susceptibility testing.
- A panel of 130 Staphylococcus aureus and 117 coagulase-negative staphylococci strains were tested.
- Minimum inhibitory concentrations (MICs) were determined for RP 59500, vancomycin, and ciprofloxacin.
Main Results:
- RP 59500 exhibited potent antistaphylococcal activity, with MICs ≤ 2 µg/mL for all tested strains.
- The activity of RP 59500 was comparable to vancomycin against both S. aureus and coagulase-negative staphylococci.
- RP 59500 and vancomycin maintained their efficacy regardless of methicillin resistance phenotype, unlike ciprofloxacin.
Conclusions:
- RP 59500 is a promising new streptogramin with broad-spectrum activity against staphylococci, including resistant strains.
- Its efficacy is not compromised by methicillin resistance, positioning it as a potential alternative to vancomycin.
- Further clinical investigation of RP 59500 is warranted for treating staphylococcal infections.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
10:35Production and Testing of Antimicrobial Peptides and Their Mimics
Published on: April 10, 2026
Related Concept Videos
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Production of Antibiotics
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
Clinical Significance of Antibiotic Resistance